Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Francis Giles, Mary Beth Rios, Kevin White, Guillermo Garcia-Manero, Alessandra Ferrajoli, Srdan Verstovsek, William Wierda, Steven Kornblau, Jorge Cortes

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

BACKGROUND. Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long-term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SCT) may be associated with a better outcome, early parameters predicting for subsequent cytogenetic responses would optimize the treatment decision-making. METHODS. The current study was performed to analyze whether early cytogenetic responses may be predictive of later major or complete cytogenetic responses to imatinib mesylate therapy in patients with Ph-positive chronic myelogenous leukemia (CML). RESULTS. Two hundred sixty-one patients with Ph-positive, chronic-phase CML after failure with interferon therapy who were treated with imatinib mesylate therapy were analyzed. A persistence of 100% Ph-positive cells after ≥ 6 months of imatinib mesylate therapy was associated with a major cytogenetic response rate of 9-13% and a complete cytogenetic response rate of 0-4%. However, a minor cytogenetic response after 3-12 months of therapy still was associated with high rates of major (68-83%) or complete (35-54%) cytogenetic response rates. CONCLUSIONS. Patients with Ph-positive, chronic-phase CML who have persistent 100% Ph-positive disease after ≥ 6 months of imatinib mesylate therapy may be offered allogeneic SCT or considered for alternative investigational therapies.

Original languageEnglish (US)
Pages (from-to)2225-2228
Number of pages4
JournalCancer
Volume97
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

    Fingerprint

Keywords

  • Chronic myelogenous leukemia (CML)
  • Cytogenetic response
  • Imatinib mesylate
  • Philadelphia chromosome (Ph)
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kantarjian, H., Talpaz, M., O'Brien, S., Giles, F., Rios, M. B., White, K., Garcia-Manero, G., Ferrajoli, A., Verstovsek, S., Wierda, W., Kornblau, S., & Cortes, J. (2003). Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 97(9), 2225-2228. https://doi.org/10.1002/cncr.11381